C16 PEG-Ceramide

Cat. No.: HY-144005

CAS No.: 212116-78-4

Molecular Formula: $(C_2H_4O)nC_{39}H_{73}NO_6$

Target: Autophagy; Liposome

Pathway: Autophagy; Metabolic Enzyme/Protease

Storage: Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description

C16 PEG-Ceramide is a polyethylene glycolylated ceramide. C16 PEG-Ceramide can be used for lipid carrier to delivery. C16 PEG-Ceramide induces autophagy. C16 PEG-Ceramide can be used for cancer research[1][2].

In Vitro

C16 PEG-Ceramide (0-118.6μM, 24 hours) has cytotoxicity and promotes autophagy in N2a cells[2].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay[2].

Cell Line:	N2a cells
Concentration:	3.7-118.6 μM
Incubation Time:	24 hours
Result:	Inhibits N2a cells activity in a dose-dependent.

Western Blot Analysis[2].

Cell Line:	N2a cells
Concentration:	2.5, 5.0, 10 and 20 μM
Incubation Time:	24 hours
Result:	Increased the LC3-II/LC3-I ratios, reduced the content of WT-Tau and P301L-Tau proteins in the cells.

REFERENCES

[1]. Su X, et, al. Co-delivery of doxorubicin and PEGylated C16-ceramide by nanoliposomes for enhanced therapy against multidrug resistance. Nanomedicine (Lond). 2015;10(13):2033-50.

[2]. Gao J, et, al. PEG-Ceramide Nanomicelles Induce Autophagy and Degrade Tau Proteins in N2a Cells. Int J Nanomedicine. 2020 Sep 11;15:6779-6789.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA